Latest News and Press Releases

60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.

All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review

Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.

60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.

60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.